Aradigm (ARDM) Stock Research, Analysis & News

Quick Analysis on Aradigm (ARDM) Stock as of December 11, 2017

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Aradigm (ARDM) Stock below)

Aradigm (ARDM) Stock Profile Summary

Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. The companys activities include development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease, inhalation anthrax infections, and smoking cessation. Its products include ARD-3100, a Phase II clinical trials product for the treatment of cystic fibrosis; ARD-3150, a Phase II clinical trials product targeting bronchiectasis; ARD-1600, a Phase I clinical trials product for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical trials product for the treatment of inhalation anthrax indications. Aradigm Corporation has a license, development, and commercialization agreement with Lung Rx to develop and commercialize inhaled treprostinil using the companys AERx Essence technology for the treatment of pulmonary arterial hypertension and other potential therapeutic indications. The company was founded in 1991 and is headquartered in Hayward, California.

Aradigm (ARDM) Stock Key Statistics Research and Analysis as of December 11, 2017

Latest Market News on Aradigm (ARDM)


Click here to find the latest news on Aradigm (ARDM)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center